The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented has been only approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.
European Society of Cardiology 2022Satellite Symposium Video August 26–29, 2022
Presentations of the Bayer Satellite Symposium at the ESC Congress 2022
Thank you for your interest! See below to watch the session recording of the Bayer Satellite Symposium at the ESC Congress 2022.
Finerenone
Sunday 28 August, 2022 | 12:45 - 13:45 CEST | On Demand
Cardiorenal benefits of finerenone: Protecting the heart and kidneys
Gerasimos Filippatos, George Bakris, Johann Bauersachs, Pam Taub, and Adriaan Voors discuss the cardiorenal protection of finerenone in patients with CKD and T2D. Patient cases with finerenone from both cardiology and nephrology perspectives are presented, as well as the importance of identifying cardiovascular risk in these patients. The rationale and study design for the upcoming phase III FINEARTS-HF trial investigating the role of finerenone in heart failure management is also discussed.
Session type: Satellite Symposium Faculty: Adriaan Voors, George Bakris, Gerasimos Filippatos, Johann Bauersachs, Pam Taub
View Video
More Information
For more information regarding Finerenone visit us by clicking the link below
The compound presented is approved for use by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D) but is investigational or being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
Date accessed: 11 July, 2022
MA-M_FIN-ALL-0987-1